Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MGNX 
MacroGenics Inc (MGNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MGNX (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 98.88% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 76.97M USD | Price to earnings Ratio - | 1Y Target Price 5.8 |
Price to earnings Ratio - | 1Y Target Price 5.8 | ||
Volume (30-day avg) 696204 | Beta 2.11 | 52 Weeks Range 1.17 - 19.54 | Updated Date 04/2/2025 |
52 Weeks Range 1.17 - 19.54 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-05 | When Before Market | Estimate -0.59 | Actual -0.818 |
Profitability
Profit Margin -44.65% | Operating Margin (TTM) -273.02% |
Management Effectiveness
Return on Assets (TTM) -24.68% | Return on Equity (TTM) -49.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -87235806 | Price to Sales(TTM) 0.51 |
Enterprise Value -87235806 | Price to Sales(TTM) 0.51 | ||
Enterprise Value to Revenue 2.69 | Enterprise Value to EBITDA -1.54 | Shares Outstanding 63090300 | Shares Floating 52340363 |
Shares Outstanding 63090300 | Shares Floating 52340363 | ||
Percent Insiders 2.25 | Percent Institutions 93.32 |
Analyst Ratings
Rating 3.64 | Target Price 7.38 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold 7 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
MacroGenics Inc
Company Overview
History and Background
MacroGenics, Inc. was founded in 2000. It is a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics for the treatment of cancer.
Core Business Areas
- Oncology: Focuses on developing antibody-based therapeutics to target and treat various cancers.
Leadership and Structure
The leadership team consists of a CEO, CFO, CSO, and other key executives. The organizational structure includes research and development, clinical operations, commercial, and administrative departments.
Top Products and Market Share
Key Offerings
- Margenza (margetuximab): Margenza is an Fc-engineered monoclonal antibody approved for the treatment of HER2-positive metastatic breast cancer. Competing drugs include Enhertu from Daiichi Sankyo and Kadcyla from Roche/Genentech. Market share and revenue from this product will depend on sales.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and regulatory hurdles. The oncology market is rapidly growing, driven by advancements in targeted therapies and immunotherapy.
Positioning
MacroGenics is positioned as a company focused on innovative antibody-based therapeutics for cancer. Its competitive advantage lies in its antibody-engineering platform.
Total Addressable Market (TAM)
The TAM for oncology therapeutics is estimated to be in the hundreds of billions of dollars. MacroGenics is positioned to capture a portion of this market through its innovative therapies. Current market cap ~$145 million.
Upturn SWOT Analysis
Strengths
- Antibody-engineering platform
- Approved product (Margenza)
- Strong research and development capabilities
- Experienced management team
Weaknesses
- Limited commercial infrastructure
- Dependence on partnerships for commercialization
- Reliance on a few key products
- History of net losses
Opportunities
- Expansion of Margenza's label
- Development of new antibody-based therapeutics
- Partnerships with larger pharmaceutical companies
- Advancements in cancer research
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Patent expirations
Competitors and Market Share
Key Competitors
- ROCHE (ROG.SW)
- DAIICHI SANKYO (DSKYF)
Competitive Landscape
MacroGenics faces intense competition from established pharmaceutical companies with greater resources and commercial infrastructure. Its advantage lies in its antibody-engineering platform and innovative therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by clinical trial progress and regulatory approvals.
Future Projections: Future growth is dependent on the commercial success of Margenza and the development of new products. Analyst estimates will vary.
Recent Initiatives: Recent initiatives include expanding the clinical development program for Margenza and pursuing partnerships for its other pipeline assets.
Summary
MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer. While the company has a validated technology and an approved product (Margenza), it faces significant challenges including competition, limited commercial infrastructure, and a history of net losses. Future success hinges on the commercial performance of Margenza and the development of its pipeline assets. The company needs to carefully manage its cash and seek partnerships to expand its reach.
Similar Companies
AGEN
Agenus Inc
AGEN
Agenus Inc
ARRY
Array Technologies Inc
ARRY
Array Technologies Inc
Sources and Disclaimers
Data Sources:
- MacroGenics Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share percentages are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MacroGenics Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2013-10-10 | President, CEO & Director Dr. Scott Koenig M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 341 | Website https://www.macrogenics.com |
Full time employees 341 | Website https://www.macrogenics.com | ||
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.